87 related articles for article (PubMed ID: 15609128)
1. Bone mineral density and adjuvant therapy in breast cancer survivors.
Crandall C; Petersen L; Ganz PA; Greendale GA
Breast Cancer Res Treat; 2004 Dec; 88(3):257-61. PubMed ID: 15609128
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
Vehmanen L; Elomaa I; Blomqvist C; Saarto T
J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
[TBL] [Abstract][Full Text] [Related]
3. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
[TBL] [Abstract][Full Text] [Related]
4. Changes on bone mineral density after adjuvant treatment in women with non-metastatic breast cancer.
Rodríguez-Rodríguez LM; Rodríguez-Rodríguez EM; Oramas-Rodríguez JM; Santolaria-Fernandez F; Llanos M; Cruz J; Martínez A; González-Reimers E; Gómez A; Batista N
Breast Cancer Res Treat; 2005 Sep; 93(1):75-83. PubMed ID: 16184462
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM; Moore TE
Cancer Nurs; 2008; 31(3):182-90. PubMed ID: 18453874
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
7. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
8. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
10. Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy.
Schwartz AL; Winters-Stone K; Gallucci B
Oncol Nurs Forum; 2007 May; 34(3):627-33. PubMed ID: 17573321
[TBL] [Abstract][Full Text] [Related]
11. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy.
Vehmanen LK; Elomaa I; Blomqvist CP; Saarto T
Acta Oncol; 2014 Jan; 53(1):75-9. PubMed ID: 23713891
[TBL] [Abstract][Full Text] [Related]
12. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure.
Shapiro CL; Phillips G; Van Poznak CH; Jackson R; Leboff MS; Woodard S; Lemeshow S
Breast Cancer Res Treat; 2005 Mar; 90(1):41-6. PubMed ID: 15770525
[TBL] [Abstract][Full Text] [Related]
13. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R
Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902
[TBL] [Abstract][Full Text] [Related]
14. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
15. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.
Brown JE; Ellis SP; Silcocks P; Blumsohn A; Gutcher SA; Radstone C; Hancock BW; Hatton MQ; Coleman RE
Clin Cancer Res; 2006 Nov; 12(21):6480-6. PubMed ID: 17085662
[TBL] [Abstract][Full Text] [Related]
16. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer.
Chen Z; Maricic M; Pettinger M; Ritenbaugh C; Lopez AM; Barad DH; Gass M; Leboff MS; Bassford TL
Cancer; 2005 Oct; 104(7):1520-30. PubMed ID: 16110508
[TBL] [Abstract][Full Text] [Related]
17. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy.
Swenson KK; Nissen MJ; Anderson E; Shapiro A; Schousboe J; Leach J
J Support Oncol; 2009; 7(3):101-7. PubMed ID: 19507458
[TBL] [Abstract][Full Text] [Related]
18. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
Saarto T; Vehmanen L; Blomqvist C; Elomaa I
J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Brufsky A; Harker WG; Beck JT; Carroll R; Tan-Chiu E; Seidler C; Hohneker J; Lacerna L; Petrone S; Perez EA
J Clin Oncol; 2007 Mar; 25(7):829-36. PubMed ID: 17159193
[TBL] [Abstract][Full Text] [Related]
20. [Bone mineral density in premenopausal and postmenopausal women between 50-55 and 50-57 years of age].
Enchev E; Botushanov N; Dzhambazova E
Akush Ginekol (Sofiia); 2007; 46(2):14-7. PubMed ID: 17469445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
